Subscribe - Individual

Subscribe - Biotech Premium (Corporate)


Top Six Picks for 2024 (Dimerix; ASX = DXB)

Dimerix - Interim Data Assessment in Mid-March

Screenshot 20240201 112927

Dimerix - Interim Data Assessment in Mid-March

Dimerix (DXB: $0.26) is conducting a registration study with its lead compound DMX-200 for the treatment of a particular kidney disease, FSGS, which is has received an orphan disease designation. Two interim data assessments are expected, with the first in mid-March. This will be a significant milestone for the company.

A positive result, according to the company, would be a statistically significant improvement in proteinurea levels which would also be clinically meaningful, with the company to proceed to the second phase of the study.

In October the company signed a licensing deal for DMX-200 with Advanz Pharma for the regions of Europe, Canada, Australia, and New Zealand. This included a $10.8 million upfront payment. If the company is directed to proceed with the study, inferring clinical benefit is being recognised, then additional licensing deals can be expected. The very high level of due diligence conducted by Advanz prior to the deal is worth recognising.

Forecasts of the FSGS disease suggest an annual addressable market of US$2.05 billion in the US alone.

In a Phase II study with DMX-200, 86% of patients achieved a drop in proteinurea levels compared to placebo, with 29% achieving more than a 40% reduction.


Bioshares recommendation: Speculative Buy Class B




Information contained in this newsletter is not a complete analysis of every material fact respecting any company, industry or security. The opinions and estimates herein expressed represent the current judgement of the publisher and are subject to change. Blake Industry and Market Analysis Pty Ltd (BIMA) and any of their associates, officers or staff may have interests in securities referred to herein (Corporations Law s.849). Details contained herein have been prepared for general circulation and do not have regard to any person’s or company’s investment objectives, financial situation and particular needs. Accordingly, no recipients should rely on any recommendation (whether express or implied) contained in this document without consulting their investment adviser (Corporations Law s.851). The persons involved in or responsible for the preparation and publication of this report believe the information herein is accurate but no warranty of accuracy is given and persons seeking to rely on information provided herein should make their own independent enquiries. Details contained herein have been issued on the basis they are only for the particular person or company to whom they have been provided by Blake Industry and Market Analysis Pty Ltd. The Directors and/or associates declare interests in the following ASX Healthcare and Biotechnology sector securities: Analyst MP: 1AD, ACR, AVR, CGS, CUV, CYC, DXB, IMM, LBT, MX1, OPT, NEU, PAB, PXS,RNO,SOM. These interests can change at any time and are not additional recommendations. Holdings in stocks valued at less than  $100 are not disclosed.